News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hadasit Ltd., Harvard Medical School, Hadassah Medical Organization and Brigham and Women's Hospital Collaborate for the First Time in a New Joint Venture to Develop a New Orally Administered Therapy for Autoimmune Diseases


1/22/2008 9:42:46 AM

JERUSALEM & BOSTON--(BUSINESS WIRE)--Hadasit, the technology transfer company of Hadassah Medical Organization in Jerusalem, Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School, announced today an equally owned joint scientific venture to develop a new orally administered therapeutic treatment for autoimmune diseases. The new product is a combination therapy that joins together both Hadasit and BWH/HMS intellectual property. This is the first official cooperation between Hadasit, Hadassah, Harvard Medical School and Brigham and Women’s Hospital.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES